Vogt P R, Brunner-LaRocca H, Sidler P, Zünd G, Truniger K, Lachat M, Turina J, Turina M I
Clinic for Cardiovascular Surgery and Cardiology, University Hospital, Rämistrasse 100, CH-8091, Zurich, Switzerland.
Eur J Cardiothorac Surg. 2000 Feb;17(2):134-9. doi: 10.1016/s1010-7940(99)00363-2.
The long-term outcome of patients with aortic bioprosthetic valves could be improved by decreasing the reoperative mortality rate.
Predictors of emergency reoperation and reoperative mortality were identified retrospectively in 172 patients who had the first bioprosthetic aortic valve replacement between 1975 and 1988 (mean age 46+/-13 years) and were subjected to replacement of the degenerated bioprostheses between 1978 and 1997 (mean age 56+/-14 years). Emergency reoperation had to be performed in 31 patients (18%).
The operative mortality was 5.2% (9/172), 22.6% for emergency (odds ratio 11.17; 95%-confidence limit 4.33-28.85) and 1.4% for elective replacement of the degenerated aortic bioprosthesis (P<0.0001; OR=20.3). Patients who died at reoperation had higher transvalvular gradients before the primary aortic valve replacement (P=0.007), received smaller bioprostheses at the first operation (P=0.03), had later recurrence of symptoms after the first aortic valve replacement (P=0.04), a higher pre-reoperative New York Heart Association (NYHA) class (P=0.02), and a higher incidence of coronary artery disease (P=0.001) and pulmonary artery hypertension (P=0.009). Endocarditis before the primary aortic valve replacement (P=0.004), postoperative pneumonia at the first operation (P=0.005), pulmonary hypertension (P=0.0004) acquired during the interval, later recurrence of symptoms (P=0.04) after the first operation, a lower ejection fraction at the time of reoperation (P=0.03) and acute onset of bioprosthetic regurgitation (P=0.00002) were predictors for emergency surgery. Higher transvalvular gradients at the primary aortic valve replacement (P=0. 006), coronary artery disease (P=0.003) acquired during the interval, the need for concomitant coronary artery revascularization (P=0. 001), sex (P=0.02) and size (P=0.05) and type of the bioprostheses used (P=0.007) were incremental predictors for reoperative mortality which were independent of emergency surgery.
Elective replacement of failed aortic bioprostheses is safe. Patients undergoing emergency reoperation have a considerably higher mortality. They can be identified by a history of native aortic valve endocarditis, higher transvalvular gradients at primary aortic valve replacement, smaller bioprostheses, and pulmonary hypertension or coronary artery disease acquired during the interval. A failing bioprosthesis must be replaced at its first sign of dysfunction.
通过降低再次手术死亡率来改善主动脉生物瓣置换患者的长期预后。
回顾性分析1975年至1988年期间首次接受生物瓣主动脉瓣置换术(平均年龄46±13岁)且于1978年至1997年期间因生物瓣退化而接受再次置换术(平均年龄56±14岁)的172例患者,确定急诊再次手术及再次手术死亡率的预测因素。31例患者(18%)需行急诊再次手术。
手术死亡率为5.2%(9/172),急诊手术死亡率为22.6%(优势比11.17;95%可信区间4.33 - 28.85),因主动脉生物瓣退化而行择期置换术的死亡率为1.4%(P<0.0001;OR = 20.3)。再次手术死亡的患者在初次主动脉瓣置换术前跨瓣压差较高(P = 0.007),首次手术时植入的生物瓣较小(P = 0.03),首次主动脉瓣置换术后症状复发较晚(P = 0.04),术前纽约心脏协会(NYHA)心功能分级较高(P = 0.02),冠状动脉疾病(P = 0.001)和肺动脉高压(P = 0.009)发生率较高。初次主动脉瓣置换术前发生心内膜炎(P = 0.004)、首次手术术后发生肺炎(P = 0.005)、随访期间出现的肺动脉高压(P = 0.0004)、首次手术术后症状复发较晚(P = 0.04)、再次手术时射血分数较低(P = 0.03)以及生物瓣反流急性发作(P = 0.00002)是急诊手术的预测因素。初次主动脉瓣置换时跨瓣压差较高(P = 0.006)、随访期间出现的冠状动脉疾病(P = 0.003)、需要同期行冠状动脉血运重建(P = 0.001)、性别(P = 0.02)、生物瓣的尺寸(P = 0.05)和类型(P = 0.007)是再次手术死亡率的递增预测因素,且与急诊手术无关。
择期置换功能失效的主动脉生物瓣是安全的。接受急诊再次手术的患者死亡率显著更高。可通过原发性主动脉瓣心内膜炎病史、初次主动脉瓣置换时较高的跨瓣压差、较小的生物瓣、随访期间出现的肺动脉高压或冠状动脉疾病来识别这些患者。生物瓣一旦出现功能障碍迹象就必须进行置换。